Transcript segment
Baric Transcribed Interview (Redacted), pp.14-15 · baric_ti:utt:00065
Page text: p.14, p.15 · original PDF
- Date
- 2026-04-10 09:00 (day precision)
- Type
- transcript segment · interview
- recipient
- Christina Salazar, Harry Kazenoff, David T. Lambeth III, William Henderson, Clark Ervin, Jake Greenberg
- speaker
- Ralph S. Baric
- Topics
- Vaccines
We had an mRNA vaccine for MERS
coronavirus that had been tested in mice, both young and
DC.Scheduling@LexitasLegal.com
old mice, and it was extremely effective. I think that
data was immediately incorporated into the discussions,
that I was not part of, but discussions at the Federal
level, in terms of prioritizing which vaccines might go
forward.
So the reason, I think, that we were particularly so
excited about that data is that most of the vaccines that I
have tested against coronaviruses, epidemic or pandemic,
not pandemic, epidemic coronaviruses like the original SARS
2003 strain, or the MERS strain, worked effectively in
young animals. But when you took them into aged animals,
where the vaccines are less affected by about tenfold, the
vaccines would fail. And the beauty about the VRC mRNA
vaccine was that the neutralizing titers in the immune
responses were as effective in the old animals as the young
animals, so they were fully protected. And that was very
impressive.